Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma

Leuk Lymphoma. 2021 Apr;62(4):999-1002. doi: 10.1080/10428194.2020.1849674. Epub 2020 Dec 16.

Authors

Affiliations

¹ Genentech, Inc, South San Francisco, CA, USA.
² Roche (China) Holding Ltd, Shanghai, China.
³ Roche Products Ltd, Welwyn Garden City, UK.
⁴ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁵ Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
⁶ Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.

PMID: 33325309
DOI: 10.1080/10428194.2020.1849674

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers
Cyclophosphamide / therapeutic use
Disease-Free Survival
Humans
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Prognosis
Progression-Free Survival
Prospective Studies
Rituximab / therapeutic use

Substances

Biomarkers
Rituximab
Cyclophosphamide